Fendler, Annika http://orcid.org/0000-0002-7267-0981
Shepherd, Scott T. C. http://orcid.org/0000-0001-6208-173X
Au, Lewis http://orcid.org/0000-0001-5877-8657
Wilkinson, Katalin A. http://orcid.org/0000-0002-9796-2040
Wu, Mary http://orcid.org/0000-0002-2074-6171
Byrne, Fiona
Cerrone, Maddalena http://orcid.org/0000-0002-6900-6086
Schmitt, Andreas M.
Joharatnam-Hogan, Nalinie
Shum, Benjamin
Tippu, Zayd
Rzeniewicz, Karolina
Boos, Laura Amanda http://orcid.org/0000-0002-4287-799X
Harvey, Ruth
Carlyle, Eleanor
Edmonds, Kim
Del Rosario, Lyra
Sarker, Sarah
Lingard, Karla
Mangwende, Mary
Holt, Lucy
Ahmod, Hamid
Korteweg, Justine
Foley, Tara
Bazin, Jessica
Gordon, William http://orcid.org/0000-0002-8166-2641
Barber, Taja
Emslie-Henry, Andrea
Xie, Wenyi
Gerard, Camille L.
Deng, Daqi
Wall, Emma C. http://orcid.org/0000-0003-2732-4497
Agua-Doce, Ana
Namjou, Sina
Caidan, Simon
Gavrielides, Mike
MacRae, James I. http://orcid.org/0000-0002-1464-8583
Kelly, Gavin http://orcid.org/0000-0001-7219-560X
Peat, Kema
Kelly, Denise
Murra, Aida
Kelly, Kayleigh
O’Flaherty, Molly
Dowdie, Lauren
Ash, Natalie
Gronthoud, Firza
Shea, Robyn L. http://orcid.org/0000-0002-7596-4555
Gardner, Gail
Murray, Darren
Kinnaird, Fiona
Cui, Wanyuan http://orcid.org/0000-0002-5077-6814
Pascual, Javier http://orcid.org/0000-0003-3874-2782
Rodney, Simon
Mencel, Justin http://orcid.org/0000-0002-1097-7953
Curtis, Olivia http://orcid.org/0000-0002-1509-7023
Stephenson, Clemency
Robinson, Anna
Oza, Bhavna
Farag, Sheima
Leslie, Isla
Rogiers, Aljosja
Iyengar, Sunil
Ethell, Mark
Messiou, Christina
Cunningham, David http://orcid.org/0000-0001-5158-1069
Chau, Ian http://orcid.org/0000-0003-0286-8703
Starling, Naureen
Turner, Nicholas
Welsh, Liam
van As, Nicholas
Jones, Robin L.
Droney, Joanne
Banerjee, Susana
Tatham, Kate C.
O’Brien, Mary
Harrington, Kevin
Bhide, Shreerang
Okines, Alicia
Reid, Alison
Young, Kate
Furness, Andrew J. S.
Pickering, Lisa http://orcid.org/0000-0002-7579-340X
Swanton, Charles http://orcid.org/0000-0002-4299-3018
Gandhi, Sonia
Gamblin, Steve http://orcid.org/0000-0001-5331-639X
Bauer, David L. V. http://orcid.org/0000-0003-3052-0368
Kassiotis, George http://orcid.org/0000-0002-8457-2633
Kumar, Sacheen http://orcid.org/0000-0002-4692-4554
Yousaf, Nadia http://orcid.org/0000-0003-2090-0025
Jhanji, Shaman http://orcid.org/0000-0002-1116-628X
Nicholson, Emma
Howell, Michael
Walker, Susanna
Wilkinson, Robert J.
Larkin, James
Turajlic, Samra http://orcid.org/0000-0001-8846-136X
,
,
Article History
Received: 18 August 2021
Accepted: 17 September 2021
First Online: 27 October 2021
Competing interests
: S.T. has received speaking fees from Roche, AstraZeneca, Novartis and Ipsen. S.T. has filed the following patents: ‘Indel mutations as a therapeutic target and predictive biomarker’ (PCTGB2018/051892 and PCTGB2018/051893) and ‘Clear Cell Renal Cell Carcinoma Biomarkers’ (P113326GB). N.Y. has received conference support from Celgene. A. Rogiers received a speaker fee from Merck Sharp & Dohme. J.L. received research funding from Bristol Myers Squibb, Merck, Novartis, Pfizer, Achilles Therapeutics, Roche, Nektar Therapeutics, Covance, Immunocore, Pharmacyclics and Aveo and served as a consultant to Achilles, AstraZeneca, Boston Biomedical, Bristol Myers Squibb, Eisai, EUSA Pharma, GlaxoSmithKline, Ipsen, Imugene, Incyte, iOnctura, Kymab, Merck Serono, Nektar, Novartis, Pierre Fabre, Pfizer, Roche Genentech, Secarna and Vitaccess. I.C. has served as a consultant to Eli Lilly, Bristol Meyers Squibb, MSD, Bayer, Roche, Merck Serono, Five Prime Therapeutics, AstraZeneca, OncXerna, Pierre Fabre, Boehringer Ingelheim, Incyte, Astellas, GSK, Sotio and Eisai and has received research funding from Eli Lilly and Janssen-Cilag. He has received honoraria from Eli Lilly, Eisai and Servier. A.O. acknowledges receipt of research funding from Pfizer and Roche; speaker fees from Pfizer, Seagen, Lilly and AstraZeneca; is an advisory board member of Roche, Seagen and AstraZeneca; has received conference support from Leo Pharmaceuticals, AstraZeneca–Daiichi Sankyo and Lilly. C. Swanton acknowledges grant support from Pfizer, AstraZeneca, Bristol Myers Squibb, Roche–Ventana, Boehringer Ingelheim, ArcherDx (collaboration in minimal residual disease sequencing technologies) and Ono Pharmaceutical; is an AstraZeneca advisory board member and the chief investigator for the MeRmaiD1 clinical trial; has consulted for Amgen, Pfizer, Novartis, GlaxoSmithKline, MSD, Bristol Myers Squibb, Celgene, AstraZeneca, Illumina, Genentech, Roche–Ventana, GRAIL, Medicxi, Metabomed, Bicycle Therapeutics and the Sarah Cannon Research Institute; has stock options in ApoGen Biotechnologies, Epic Bioscience and GRAIL; and has stock options in and is a cofounder of Achilles Therapeutics. C. Swanton holds European patents relating to assay technology to detect tumor recurrence (PCT/GB2017/053289), target neoantigens (PCT/EP2016/059401), identify patient response to immune-checkpoint blockade (PCT/EP2016/071471), determine HLA LOH (PCT/GB2018/052004), predict survival rates of patients with cancer (PCT/GB2020/050221) and identify patients who respond to cancer treatment (PCT/GB2018/051912); a US patent related to detecting tumor mutations (PCT/US2017/28013); and both a European and US patent related to identifying insertion and deletion mutation targets (PCT/GB2018/051892). L.P. has received research funding from Pierre Fabre and honoraria from Pfizer, Ipsen, Bristol Myers Squibb and EUSA Pharma. S. Banerjee has received institutional research funding from AstraZeneca, Tesaro and GSK; speaker fees from Amgen, Pfizer, AstraZeneca, Tesaro, GSK, Clovis, Takeda, ImmunoGen and Mersana; and has an advisor role for Amgen, AstraZeneca, Epsilogen, Genmab, ImmunoGen, Mersana, MSD, Merck Serono, OncXerna, Pfizer and Roche. W.C. has received honoraria from Janssen and AstraZeneca. A.F., S.T.C.S., L.A., K.A.W., M.W., F.B., M.C., A.M.S., N.J.-H., B.S., Z.T., K.R., L.A.B., R.H., E.C., K.E., L.D.R., S.S., K.L., M.M., L.H., H.A., J.K., T.F., J.B., W.G., T.B., A.E.-H., W.X., C.L.G., D.D., E.C.W., A.A.-D., S.N., S.C., M.G., J.I.M., G. Kelly, K.P., D.K., A.M., K.K., M.O’F., L.D., N.A., F.G., R.L.S., G.G., D.M., F.K., W.C., J.P., S.R., J.M., O.C., C. Stephenson, B.O., S.F., I.L., A. Reid, S.I., M.E., C.M., D.C., N.S., N.T., L.W., N.v.A., R.L.J., J.D., K.C.T., M.O’B., K.H., S. Bhide, K.Y., A.J.S.F., S. Gamblin, D.L.V.B., G. Kassiotis, S.K., N.Y., S.J., E.N., M.H., S.W. and R.J.W. have no conflicts of interest to declare.